THE DISCOVERY PROCESS

The process of discovering new antibiotics involves a wide range of bacterial cell targets, antibacterial agents and technical approaches. Here is an overview of these elements.

 

To find researchers in each of these areas, please visit the Registry page. You will need to be a member to access this page.

Bacteria cellular target and antibacterial agents

Discovery Process no labels copy copy (6

PABA

DHF

THF

Metabolic pathways

-Sulfonamides

-Trimethoprim

-Bacteriocins

-Isoniazid

-Lipopeptides

-Macrolides

-Microcins

-Nisin

-Polypeptides

-Aminocoumarins

-Aminonucleosides

-Ansamycins

-Antitubercular agents

-Epothilones

-(Fluoro)quinolones

-Aminoglycosides

-Amphenicols

-Glycylcycline

-Lincosamides

-Macrolides

-Mupirocin

-Nitrofurans

-Oxazolidinones

-Pleuromutilin

-Puromycin

-Streptogramins

-Tetracyclines

-Tigecycline

beta-lactams:

-Carbapenems

-Cephalosporins

-Monobactams

-Penicillins

-Alafosfalin

-Cycloserine

-Fosfomycin

-Glycopeptides

-Polypeptides

Source of Agent

Discovery Process no labels copy copy (4
Discovery Process no labels copy copy (3
Synthetic Products

Hit Discovery

Synthesis & isolation
Combinatorial chemistry
Assay development
Screening
In silico screening
In silico discovery
Metagenomics
Heterologous expression
Bioinformatics

Development Pipeline

Click on the blue boxes to expand

Analytical Methods

Target Identification

Structure elucidation
Mass spectrometry
X-ray cystallography
Metabolomics
16s genomics
Whole genome
Proteomics
Transcriptomics
Electron microscopy

Legal

Medicinal

Chemistry

In Vitro

Studies

Library development
In silico drug design
Structure activity studies
Drug affinity and selectivity
Cellular disease models
Mechanisms of action
Lead candidate refinement
Intellectual property
Risk assessment

In Vivo

Studies

In vivo assays
In vivo analysis
Proof of concept
Drug delivery

Target Validation

Knock out
Chemogenetics

Clinical

Trials

Phase I